Tracks breath and blood markers of airway inflammation in COPD over one year
Follows adults with COPD for a year, checking breath and blood markers of airway inflammation.
Plain-language title generated from the registry record
Registry title: Biannual Review of Exhaled Air and Trends in Health Evaluation in COPD
Key facts
- Where
- Jette, BelgiumSee the site
Where in Belgium
- Universitair Ziekenhuis BrusselJette, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitair Ziekenhuis Brussel
- Trial code
- NCT07045948
- Record updated
- 11 September 2025
- Original description
This study aims to evaluate how airway inflammation, lung function, and symptoms change over time in people with chronic obstructive pulmonary disease (COPD). Airway inflammation will be assessed using a simple breath test (FeNO) and a small blood sample to measure eosinophils, a type of white blood cell. Participants will be followed for one year, with three study visits (at the start, 6 months, and 12 months). The goal is to understand how these markers evolve and whether they differ between people who experience a worsening of symptoms (called exacerbations) and those who remain stable. All tests except for a small extra blood draw are part of routine COPD care. Participation does not affect standard treatment.Read full original descriptionShow less
Biannual Review of Exhaled Air and Trends in Health Evaluation in COPD
This study aims to evaluate how airway inflammation, lung function, and symptoms change over time in people with chronic obstructive pulmonary disease (COPD). Airway inflammation will be assessed using a simple breath test (FeNO) and a small blood sample to measure eosinophils, a type of white blood cell. Participants will be followed for one year, with three study visits (at the start, 6 months, and 12 months). The goal is to understand how these markers evolve and whether they differ between people who experience a worsening of symptoms (called exacerbations) and those who remain stable. All tests except for a small extra blood draw are part of routine COPD care. Participation does not affect standard treatment.
Inclusion: Adults aged ≥ 40 years; Diagnosed with COPD according to GOLD criteria; Attending routine follow-up visits every 6 months; Ability to provide informed consent.
Exclusion: Recent respiratory tract infection or exacerbation (either moderate or se-vere) (<4 weeks before inclusion); Dominant asthmatic phenotype (ACO with asthma predominance); Severe comorbidities interfering with participation or follow-up.